From: Protecting the underscreened women in developed countries: the value of HPV test
NEGATIVE HPV TEST AT BASELINE | TOTAL SAMPLE N (%) | TOTAL FOLLOW UP SAMPLE N (%) | DIAGNOSIS AT LAST FOLLOW UP | |||||||
---|---|---|---|---|---|---|---|---|---|---|
NORMAL N (%) | ASC-US/ASC-H N (%) | CIN1aN (%) | CIN2a | CIN3aN (%) | CERVICAL CARCINOMAabN (%) | OTHERS RESULTScN (%) | ||||
CONCOMITANT CYTOLOGY RESULT AT BASELINE | Normal | 1693 (99.1)d | 654 (98.2) | 641 (98.3)e | 1 (100) | 1 (100) | 1 (100)f | 10 (90.9) | ||
ASC-US/ASC H/AGC/LSIL | 15 (0.8) | 11 (1.7) | 10 (1.5) | 1 (9.1) | ||||||
Suspected adenocarcinomag | 1 (0.1) | 1 (0.2) | 1 (0.2) | |||||||
TOTAL | 1709 (100) | 666 (100) | 652 (100) | 1 (100) | 1 (100) | 1 (100) | 11 (100) | |||
POSITIVE HPV TEST AT BASELINE | TOTAL SAMPLE N (%) | TOTAL FOLLOW UP SAMPLE N (%) | ||||||||
CONCOMITANT CYTOLOGY RESULT AT BASELINE | Normal | 99 (80.5)d | 78 (77.2) | 45 (83.3) | 6 (100) | 2 (25.0) | 6 (75) | 3(42.9) | 16 (100) | |
ASC-US/AGC/LSIL | 19 (15.4) | 18 (17.8) | 9 (16.7) | 5 (62.5) | 1 (12.5) | 1 (14.3) | 2 (100) | |||
HSIL | 5 (4.1) | 5 (5.0) | 1 (12.5) | 1 (12.5) | 3 (42.9) | |||||
TOTAL | 123 (100) | 101 (100) | 54 (100) | 6 (100) | 8 (100) | 8 (100) | 7 (100) | 2 (100) | 16 (100) |